Burning Rock Biotech vs Caris Life Sciences
BNR and CAI side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BNR and CAI compare
Caris Life Sciences grew revenue faster over the last twelve months (85.4% versus 4.6% for Burning Rock Biotech).
Caris Life Sciences keeps more of each dollar of sales as profit, with a net margin of 10.6% compared with −10.3% at Burning Rock Biotech.
Caris Life Sciences scores higher on the StockData Score (8 against 4 for Burning Rock Biotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BNR | CAI |
|---|---|---|
| Size and price | ||
| Market cap | – | $9.7B |
| Share price | $10.90 | $34.33 |
| Change, 1 year | −13.0% | 16.6% |
| Change, 5 years | −92.6% | – |
| Beta (5Y) | 1.79 | 2.10 |
| Employees | 667 | 1,846 |
| StockData Score | ||
| Total score | 4 | 8 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 1 | 3 (better) |
| Health score | 2 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 9.8× |
| P/B | – | 16.4× |
| EV/EBITDA | – | 57.4× |
| P/FCF | – | 78.3× |
| FCF yield | – | 1.3% |
| Fair value | – | $14.85 |
| Margin of safety | – | −131% |
| Growth | ||
| Revenue growth (TTM) | 4.6% | 85.4% (better) |
| Revenue growth, 5Y average | 4.6% | – |
| Profitability | ||
| Gross margin | 74.7% | – |
| Operating margin | −10.2% | 15.5% (better) |
| Net margin | −10.3% | 10.6% (better) |
| FCF margin | −6.2% | 12.5% (better) |
| Return on equity | −9.9% | 20.1% (better) |
| Return on invested capital | −72.5% | 31.0% (better) |
| Financial health | ||
| Debt / equity | 0.00 (better) | 0.66 |
| Net debt / EBITDA | – | 1.67 |
| Interest coverage | – | 3.3× |
| Current ratio | 2.99 | 5.53 (better) |
| Altman Z-score | – | 8.28 |
| Piotroski F-score | 5 | 6 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 0.22% |
| Shareholder yield | – | 0.22% |
| Ownership | ||
| Held by institutions | 1.8% | 54.5% |
| Held by insiders | 19.0% | 64.1% |
| Insider net buying, 12 months | $11.6M (better) | −$27.3M |
| Superinvestors holding | – | 2 |
| Short interest, % of float | – | 13.7% |
Go deeper
- BNR stock overview
- BNR income statement
- BNR valuation and score
- CAI stock overview
- CAI income statement
- CAI valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.